NASDAQ:BLFS BioLife Solutions Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding BioLife Solutions, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $14.64 +0.83 (+6.01%) (As of 07/1/2022 08:44 PM ET) Add Compare Share Today's Range$13.67▼$14.7650-Day Range$10.54▼$15.7252-Week Range$10.40▼$60.67Volume355,400 shsAverage Volume433,817 shsMarket Capitalization$620.88 millionP/E RatioN/ADividend YieldN/APrice Target$42.17 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media BioLife Solutions MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside188.0% Upside$42.17 Price TargetShort InterestBearish12.02% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.07Based on 9 Articles This WeekInsider TradingSelling Shares$2.33 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.39) to $0.24 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.1.88 out of 5 starsMedical Sector637th out of 1,412 stocksElectromedical Equipment Industry10th out of 30 stocks 3.5 Analyst's Opinion Consensus RatingBioLife Solutions has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $42.17, BioLife Solutions has a forecasted upside of 188.0% from its current price of $14.64.Amount of Analyst CoverageBioLife Solutions has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted12.02% of the float of BioLife Solutions has been sold short.Short Interest Ratio / Days to CoverBioLife Solutions has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioLife Solutions has recently increased by 3.33%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldBioLife Solutions does not currently pay a dividend.Dividend GrowthBioLife Solutions does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BLFS. Previous Next 2.3 News and Social Media Coverage News SentimentBioLife Solutions has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for BioLife Solutions this week, compared to 1 article on an average week.Search Interest2 people have searched for BLFS on MarketBeat in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioLife Solutions insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,332,296.00 in company stock.Percentage Held by InsidersOnly 5.90% of the stock of BioLife Solutions is held by insiders.Percentage Held by Institutions83.48% of the stock of BioLife Solutions is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for BioLife Solutions are expected to grow in the coming year, from ($0.39) to $0.24 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioLife Solutions is -41.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioLife Solutions is -41.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioLife Solutions has a P/B Ratio of 1.24. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive BLFS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioLife Solutions and its competitors with MarketBeat's FREE daily newsletter. Email Address About BioLife Solutions (NASDAQ:BLFS) StockBioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.Read More BLFS Stock News HeadlinesJuly 2, 2022 | americanbankingnews.comMichael Rice Sells 889 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) StockJuly 2, 2022 | americanbankingnews.comAby J. Mathew Sells 704 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) StockJune 17, 2022 | finance.yahoo.comBioLife Solutions Deploys SciSafe's Ultra Low Controlled Temperature Trailers to Extend Domestic Cold Chain ServicesJune 2, 2022 | finance.yahoo.comInvesting in BioLife Solutions (NASDAQ:BLFS) five years ago would have delivered you a 496% gainMay 9, 2022 | finance.yahoo.comBioLife Solutions, Inc. (BLFS) Reports Q1 Loss, Lags Revenue EstimatesMay 9, 2022 | investing.comBioLife Solutions Tops Q1 EPS by 8cMay 9, 2022 | finance.yahoo.comBioLife Solutions Reports First Quarter 2022 Financial ResultsApril 25, 2022 | seekingalpha.comBioLife Solutions gains as Oppenheimer upgrades on valuationApril 7, 2022 | bizjournals.comBioLife Plasma Services expanding footprint with Roseville locationApril 7, 2022 | finance.yahoo.comBioLife Solutions, Inc. Announces Change of Auditor to Grant Thornton LLPMarch 21, 2022 | seekingalpha.comBioLife Solutions receives Nasdaq notice for noncomplianceMarch 18, 2022 | finance.yahoo.comBioLife Solutions Receives Nasdaq Notice of Noncompliance for Delayed 10-K FilingMarch 17, 2022 | finance.yahoo.comBioLife Solutions Announces Additional Delay in Filing of Annual Report on Form 10-KMarch 15, 2022 | benzinga.comBioLife Solutions Offers FY22 Guidance, Outlines Expected CatalystsMarch 15, 2022 | finance.yahoo.comBioLife Solutions Secures Strategic Customer Wins and Plans 2022 Expansion in $400 Million Biostorage Services MarketMarch 1, 2022 | finance.yahoo.comBioLife Solutions to Attend and Present at Upcoming Investor ConferencesFebruary 28, 2022 | markets.businessinsider.comBioLife Solutions Reports Unaudited Fourth Quarter and Full Year 2021 Financial ResultsFebruary 27, 2022 | seekingalpha.comBioLife Solutions Q4 2021 Earnings PreviewFebruary 21, 2022 | finance.yahoo.comBioLife Solutions to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update on February 28, 2022February 17, 2022 | nasdaq.comBiolife Solutions Inc Shares Approach 52-Week Low - Market MoverFebruary 2, 2022 | finance.yahoo.comIs BioLife Solutions (NASDAQ:BLFS) Using Too Much Debt?January 27, 2022 | finance.yahoo.comPeoples Bank Buys BioLife Solutions Inc, iShares 0-5 Year TIPS Bond ETF, SPDR Portfolio Short ...January 10, 2022 | finance.yahoo.comBioLife Solutions Announces Preliminary 2021 Revenue of $119 Million, Up 148% Over 2020January 3, 2022 | nasdaq.comWhat Type Of Shareholders Make Up BioLife Solutions, Inc.'s (NASDAQ:BLFS) Share Registry?December 16, 2021 | finance.yahoo.comBiolife Solutions Inc (BLFS) CEO Michael Rice Sold $1.1 million of SharesSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Electromedical equipment Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BLFS CUSIPN/A CIK834365 Webwww.biolifesolutions.com Phone(425) 402-1400Fax425-402-1433Employees432Year FoundedN/ACompany Calendar Last Earnings5/09/2022Today7/03/2022Next Earnings (Estimated)8/11/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$42.17 High Stock Price Forecast$65.00 Low Stock Price Forecast$30.00 Forecasted Upside/Downside+188.0%Consensus RatingBuy Rating Score (0-4)3 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.350010) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7.64 million Net Margins-10.35% Pretax Margin-24.76% Return on Equity-6.24% Return on Assets-5.45% Debt Debt-to-Equity Ratio0.01 Current Ratio3.39 Quick Ratio2.53 Sales & Book Value Annual Sales$119.16 million Price / Sales5.21 Cash FlowN/A Price / Cash FlowN/A Book Value$11.80 per share Price / Book1.24Miscellaneous Outstanding Shares42,410,000Free Float39,908,000Market Cap$620.88 million OptionableNot Optionable Beta1.91 BioLife Solutions Frequently Asked Questions Should I buy or sell BioLife Solutions stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioLife Solutions in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BioLife Solutions stock. View analyst ratings for BioLife Solutions or view top-rated stocks. What is BioLife Solutions' stock price forecast for 2022? 6 Wall Street research analysts have issued 1-year price targets for BioLife Solutions' stock. Their BLFS stock forecasts range from $30.00 to $65.00. On average, they anticipate BioLife Solutions' stock price to reach $42.17 in the next year. This suggests a possible upside of 188.0% from the stock's current price. View analysts' price targets for BioLife Solutions or view top-rated stocks among Wall Street analysts. How has BioLife Solutions' stock performed in 2022? BioLife Solutions' stock was trading at $37.27 at the beginning of 2022. Since then, BLFS stock has decreased by 60.7% and is now trading at $14.64. View the best growth stocks for 2022 here. When is BioLife Solutions' next earnings date? BioLife Solutions is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022. View our earnings forecast for BioLife Solutions. How were BioLife Solutions' earnings last quarter? BioLife Solutions, Inc. (NASDAQ:BLFS) released its quarterly earnings data on Monday, May, 9th. The medical equipment provider reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by $0.06. The medical equipment provider had revenue of $36.22 million for the quarter, compared to analyst estimates of $37.87 million. BioLife Solutions had a negative trailing twelve-month return on equity of 6.24% and a negative net margin of 10.35%. During the same period in the previous year, the business posted $0.01 EPS. View BioLife Solutions' earnings history. What guidance has BioLife Solutions issued on next quarter's earnings? BioLife Solutions issued an update on its FY 2022 earnings guidance on Monday, June, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $159.50 million-$171.00 million, compared to the consensus revenue estimate of $165.38 million. Who are BioLife Solutions' key executives? BioLife Solutions' management team includes the following people: Mr. Michael P. Rice, Chairman & CEO (Age 59, Pay $1.24M)Mr. Roderick de Greef, Pres & COO (Age 62, Pay $635.99k)Mr. Troy Wichterman, Chief Financial Officer (Age 37, Pay $290.72k) (LinkedIn Profile)Dr. Aby J. Mathew, Chairman of Scientific Advisory Board, Exec. VP & Chief Scientific Officer (Age 50, Pay $638.79k)Mr. Marcus Schulz, Chief Revenue Officer (Age 43, Pay $778.22k) (LinkedIn Profile)Mr. Todd Berard, Chief Marketing Officer (Age 53) (LinkedIn Profile)Ms. Sarah Aebersold J.D., VP of Global HR (Age 46) (LinkedIn Profile)Ms. Karen Foster, Chief Quality Officer (Age 62) (LinkedIn Profile) What is Mike Rice's approval rating as BioLife Solutions' CEO? 5 employees have rated BioLife Solutions CEO Mike Rice on Glassdoor.com. Mike Rice has an approval rating of 100% among BioLife Solutions' employees. This puts Mike Rice in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are some of BioLife Solutions' key competitors? Some companies that are related to BioLife Solutions include InMode (INMD), Natus Medical (NTUS), TransMedics Group (TMDX), Outset Medical (OM), Cutera (CUTR), ViewRay (VRAY), AxoGen (AXGN), Zynex (ZYXI), Edap Tms (EDAP), Semler Scientific (SMLR), Hyperfine (HYPR), Stereotaxis (STXS), FONAR (FONR), Electromed (ELMD) and Electromed (ELMD). View all of BLFS's competitors. What other stocks do shareholders of BioLife Solutions own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioLife Solutions investors own include (CGC), Micron Technology (MU), AbbVie (ABBV), Cara Therapeutics (CARA), Gilead Sciences (GILD), Pfizer (PFE), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Twilio (TWLO) and Verastem (VSTM). What is BioLife Solutions' stock symbol? BioLife Solutions trades on the NASDAQ under the ticker symbol "BLFS." How do I buy shares of BioLife Solutions? Shares of BLFS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is BioLife Solutions' stock price today? One share of BLFS stock can currently be purchased for approximately $14.64. How much money does BioLife Solutions make? BioLife Solutions (NASDAQ:BLFS) has a market capitalization of $620.88 million and generates $119.16 million in revenue each year. The medical equipment provider earns $-7.64 million in net income (profit) each year or ($0.350010) on an earnings per share basis. How many employees does BioLife Solutions have? BioLife Solutions employs 432 workers across the globe. How can I contact BioLife Solutions? BioLife Solutions' mailing address is 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021. The official website for BioLife Solutions is www.biolifesolutions.com. The medical equipment provider can be reached via phone at (425) 402-1400, via email at rdegreef@biolifesolutions.com, or via fax at 425-402-1433. This page (NASDAQ:BLFS) was last updated on 7/4/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
